acquir acquir integr dna technolog privat
approxim billion ebitda incl cash tax benefit
cash debt oper stand-alone busi within
dhr life scienc segment manufactur consum reagent
biolog gene edit molecular diagnost transact expect
close ad million annual revenu
grow healthi mid-teen compound-annual-growth-rate past three year bolster
exposur all-import recur consum revenu stream
gross margin ebitda margin profil track well ahead
consolid busi make chang
ep lift ep deal accret
tp move higher view
detail add exposur rapidli growth genom reagent market
agricultur clinic diagnost industri revenu
us leverag global presenc scale suspect db
tool enhanc revenu profit growth complement
exist beckman coulter life scienc genom cepheid pcr
busi opportun margin expans longer term
capit deploy kicker transact come heel
boost estim deal repres largest transact
life scienc sinc pall expect continu behind
reload balanc sheet focu like fairli balanc across
non-dent busi focu consum revenu stream
consist deal risk call includ acquisit miscu
fundament demand regulatori shift
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
lead manufactur system instrument
consum broad array purpos custom
diagnost dental environment health/appli scienc
price rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
acceler key end market global signific rebound
dental trend better expect implement db
acquir compani market share gain materi margin
grey sky scenario base signific weak
key end market prolong weak dental demand trend
deceler core growth acquisit integr headwind
compani mention price
